378 related articles for article (PubMed ID: 32492074)
1. The impact of atlas-based MR attenuation correction on the diagnosis of FDG-PET/MR for Alzheimer's diseases- A simulation study combining multi-center data and ADNI-data.
Sekine T; Buck A; Delso G; Kemp B; Ter Voert EEGW; Huellner M; Veit-Haibach P; Kaushik S; Wiesinger F; Warnock G;
PLoS One; 2020; 15(6):e0233886. PubMed ID: 32492074
[TBL] [Abstract][Full Text] [Related]
2. Zero Echo Time MRAC on FDG-PET/MR Maintains Diagnostic Accuracy for Alzheimer's Disease; A Simulation Study Combining ADNI-Data.
Ando T; Kemp B; Warnock G; Sekine T; Kaushik S; Wiesinger F; Delso G
Front Neurosci; 2020; 14():569706. PubMed ID: 33324141
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Atlas-Based Attenuation Correction for Integrated PET/MR in Human Brain: Application of a Head Atlas and Comparison to True CT-Based Attenuation Correction.
Sekine T; Buck A; Delso G; Ter Voert EE; Huellner M; Veit-Haibach P; Warnock G
J Nucl Med; 2016 Feb; 57(2):215-20. PubMed ID: 26493207
[TBL] [Abstract][Full Text] [Related]
4. Optimization of Statistical Single Subject Analysis of Brain FDG PET for the Prognosis of Mild Cognitive Impairment-to-Alzheimer's Disease Conversion.
Lange C; Suppa P; Frings L; Brenner W; Spies L; Buchert R
J Alzheimers Dis; 2016; 49(4):945-959. PubMed ID: 26577523
[TBL] [Abstract][Full Text] [Related]
5. Effects of imaging modalities, brain atlases and feature selection on prediction of Alzheimer's disease.
Ota K; Oishi N; Ito K; Fukuyama H; ;
J Neurosci Methods; 2015 Dec; 256():168-83. PubMed ID: 26318777
[TBL] [Abstract][Full Text] [Related]
6. Potential Clinical Value of Multiparametric PET in the Prediction of Alzheimer's Disease Progression.
Chen X; Zhou Y; Wang R; Cao H; Reid S; Gao R; Han D;
PLoS One; 2016; 11(5):e0154406. PubMed ID: 27183116
[TBL] [Abstract][Full Text] [Related]
7. ZTE MR-based attenuation correction in brain FDG-PET/MR: performance in patients with cognitive impairment.
Sgard B; Khalifé M; Bouchut A; Fernandez B; Soret M; Giron A; Zaslavsky C; Delso G; Habert MO; Kas A
Eur Radiol; 2020 Mar; 30(3):1770-1779. PubMed ID: 31748857
[TBL] [Abstract][Full Text] [Related]
8. Prediction of Progressive Mild Cognitive Impairment by Multi-Modal Neuroimaging Biomarkers.
Xu L; Wu X; Li R; Chen K; Long Z; Zhang J; Guo X; Yao L;
J Alzheimers Dis; 2016; 51(4):1045-56. PubMed ID: 26923024
[TBL] [Abstract][Full Text] [Related]
9. Quantitative analysis of MRI-guided attenuation correction techniques in time-of-flight brain PET/MRI.
Mehranian A; Arabi H; Zaidi H
Neuroimage; 2016 Apr; 130():123-133. PubMed ID: 26853602
[TBL] [Abstract][Full Text] [Related]
10. Longer-Term Investigation of the Value of 18F-FDG-PET and Magnetic Resonance Imaging for Predicting the Conversion of Mild Cognitive Impairment to Alzheimer's Disease: A Multicenter Study.
Inui Y; Ito K; Kato T;
J Alzheimers Dis; 2017; 60(3):877-887. PubMed ID: 28922157
[TBL] [Abstract][Full Text] [Related]
11. Multi-Atlas-Based Attenuation Correction for Brain 18F-FDG PET Imaging Using a Time-of-Flight PET/MR Scanner: Comparison with Clinical Single-Atlas- and CT-Based Attenuation Correction.
Sekine T; Burgos N; Warnock G; Huellner M; Buck A; Ter Voert EE; Cardoso MJ; Hutton BF; Ourselin S; Veit-Haibach P; Delso G
J Nucl Med; 2016 Aug; 57(8):1258-64. PubMed ID: 27013697
[TBL] [Abstract][Full Text] [Related]
12. Biomarker-Based Prediction of Progression to Dementia: F-18 FDG-PET in Amnestic MCI.
Tripathi M; Tripathi M; Parida GK; Kumar R; Dwivedi S; Nehra A; Bal C
Neurol India; 2019; 67(5):1310-1317. PubMed ID: 31744965
[TBL] [Abstract][Full Text] [Related]
13. Clinical Evaluation of Zero-Echo-Time Attenuation Correction for Brain 18F-FDG PET/MRI: Comparison with Atlas Attenuation Correction.
Sekine T; Ter Voert EE; Warnock G; Buck A; Huellner M; Veit-Haibach P; Delso G
J Nucl Med; 2016 Dec; 57(12):1927-1932. PubMed ID: 27339875
[TBL] [Abstract][Full Text] [Related]
14. Predicting cognitive decline in subjects at risk for Alzheimer disease by using combined cerebrospinal fluid, MR imaging, and PET biomarkers.
Shaffer JL; Petrella JR; Sheldon FC; Choudhury KR; Calhoun VD; Coleman RE; Doraiswamy PM;
Radiology; 2013 Feb; 266(2):583-91. PubMed ID: 23232293
[TBL] [Abstract][Full Text] [Related]
15. Visual Rating and Computer-Assisted Analysis of FDG PET in the Prediction of Conversion to Alzheimer's Disease in Mild Cognitive Impairment.
Kang JM; Lee JY; Kim YK; Sohn BK; Byun MS; Choi JE; Son SK; Im HJ; Lee JH; Ryu YH; Lee DY
Mol Diagn Ther; 2018 Aug; 22(4):475-483. PubMed ID: 29761365
[TBL] [Abstract][Full Text] [Related]
16. Joint Assessment of Quantitative 18F-Florbetapir and 18F-FDG Regional Uptake Using Baseline Data from the ADNI.
Ben Bouallègue F; Mariano-Goulart D; Payoux P;
J Alzheimers Dis; 2018; 62(1):399-408. PubMed ID: 29439345
[TBL] [Abstract][Full Text] [Related]
17. Comparison of neuroimaging modalities for the prediction of conversion from mild cognitive impairment to Alzheimer's dementia.
Trzepacz PT; Yu P; Sun J; Schuh K; Case M; Witte MM; Hochstetler H; Hake A;
Neurobiol Aging; 2014 Jan; 35(1):143-51. PubMed ID: 23954175
[TBL] [Abstract][Full Text] [Related]
18. Accurate Prediction of Conversion to Alzheimer's Disease using Imaging, Genetic, and Neuropsychological Biomarkers.
Dukart J; Sambataro F; Bertolino A
J Alzheimers Dis; 2016; 49(4):1143-59. PubMed ID: 26599054
[TBL] [Abstract][Full Text] [Related]
19. Volume of interest-based [18F]fluorodeoxyglucose PET discriminates MCI converting to Alzheimer's disease from healthy controls. A European Alzheimer's Disease Consortium (EADC) study.
Pagani M; De Carli F; Morbelli S; Öberg J; Chincarini A; Frisoni GB; Galluzzi S; Perneczky R; Drzezga A; van Berckel BN; Ossenkoppele R; Didic M; Guedj E; Brugnolo A; Picco A; Arnaldi D; Ferrara M; Buschiazzo A; Sambuceti G; Nobili F
Neuroimage Clin; 2015; 7():34-42. PubMed ID: 25610765
[TBL] [Abstract][Full Text] [Related]
20. Cognitive Composites Domain Scores Related to Neuroimaging Biomarkers within Probable-Amnestic Mild Cognitive Impairment-Storage Subtype.
Espinosa A; Alegret M; Pesini P; Valero S; Lafuente A; Buendía M; San José I; Ibarria M; Tejero MA; Giménez J; Ruiz S; Hernández I; Pujadas F; Martínez-Lage P; Munuera J; Arbizu J; Tárraga L; Hendrix SB; Ruiz A; Becker JT; Landau SM; Sotolongo-Grau O; Sarasa M; Boada M; ;
J Alzheimers Dis; 2017; 57(2):447-459. PubMed ID: 28269787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
